Data to ponder: 5% of patients in the 95% immunized group experience on (zero) deaths from infections.
All important question about the efficacy of one dose: how many people in the 50% immunized group (one dose) who get infected will get very sick or die? If only half as many as non-immunized: that leads to one policy. If only one-twentieth as many severe illnesses and/or deaths than unvaccinated: that leads to a very different policy of distribution — not getting severely ill and not dying being the policy equivalent of not getting infected at all.
Data to ponder: 5% of patients in the 95% immunized group experience on (zero) deaths from infections.
All important question about the efficacy of one dose: how many people in the 50% immunized group (one dose) who get infected will get very sick or die? If only half as many as non-immunized: that leads to one policy. If only one-twentieth as many severe illnesses and/or deaths than unvaccinated: that leads to a very different policy of distribution — not getting severely ill and not dying being the policy equivalent of not getting infected at all.
History will let us know.
@Denis,
That’s why we do clinical trials instead of relying on pundits and speculation.